Core Insights - Sanofi's brivekimig demonstrated positive results in the phase 2a HS-OBTAIN study for treating moderate-to-severe hidradenitis suppurativa (HS) [2][4][10] - The treatment showed clinically meaningful improvements in the primary endpoint, HiSCR50, with a median response rate of 67% in the brivekimig group compared to 37% in the placebo group [8] - Brivekimig was well tolerated, with no serious adverse events reported, and the most common adverse events were nasopharyngitis and headache [5][6] Study Details - The HS-OBTAIN study was a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of brivekimig in biologic-naïve adults with moderate-to-severe HS [10][11] - Patients were randomized 2:1 to receive brivekimig 150 mg or placebo subcutaneously every two weeks for 16 weeks [11] - Key secondary endpoints also showed significant improvements, with 54% of patients achieving HiSCR75 and 31% achieving HiSCR90 in the brivekimig group compared to 22% and 9% in the placebo group, respectively [8] Mechanism and Future Directions - Brivekimig is a dual-target Nanobody® molecule that inhibits tumor necrosis factor (TNF) and OX40-ligand, which are crucial in inflammatory pathways [7][9] - The results indicate that targeting both TNF and OX40L pathways may provide a promising strategy for reducing inflammation in HS [4][6] - Sanofi is committed to exploring brivekimig further and its potential impact on chronic inflammatory skin diseases [6][12]

Core Insights - The market potential for Atopic Dermatitis (AD) is significant, with a large patient population and unmet medical needs, particularly for effective and safe treatments [1][2] - The development of small molecules and biologics is entering a new phase, with several new therapies gradually being approved for AD treatment [2][3] - JAK inhibitors show excellent efficacy but have safety concerns, while TYK2 is emerging as a promising new option with potentially higher safety [3][4] - Biologics such as IL-4Rα and IL-31 demonstrate strong efficacy in improving skin lesions and alleviating itching, but there is still room for improvement compared to JAK inhibitors [4][5] - Dual and multi-target antibodies may offer a new approach by combining the advantages of different targets, with several companies already exploring this strategy [5] Group 1: Market Overview - Atopic Dermatitis (AD) is a chronic, recurrent inflammatory skin disease characterized by severe itching, affecting approximately 600-700 million patients globally, with around 67 million in China [1] - The demand for effective and safe medications is high due to the significant burden of the disease on patients' daily lives [1] Group 2: Treatment Landscape - Traditional therapies have poor safety profiles, leading to the emergence of biologics and small molecule targeted therapies over the past decade, with about a dozen products approved globally [2] - Current approved small molecule JAK inhibitors include Upadacitinib and Abrocitinib, but they carry safety warnings from the FDA [3] Group 3: Biologics Efficacy - Among the biologics, IL-4Rα and IL-13 show confirmed efficacy, while IL-31 is particularly effective in alleviating itching [4] - There is a notable difference in efficacy between biologics and JAK inhibitors, with Upadacitinib showing superior results in head-to-head studies [4] Group 4: Future Directions - The exploration of dual/multi-target antibodies aims to enhance treatment efficacy and extend dosing intervals, with several companies already developing such therapies [5] - Ongoing research into various targets may lead to improved outcomes for AD patients [5]

Summary of Nurix Therapeutics Conference Call Company Overview - **Company**: Nurix Therapeutics (NasdaqGM:NRIX) - **Date**: September 16, 2025 - **Focus**: Development of Bexabritadeg and its applications in autoimmune diseases and oncology Key Points Industry and Product Focus - **Bexabritadeg**: A BTK degrader with potential applications in autoimmune diseases and chronic lymphocytic leukemia (CLL) [3][12] - **BTK (Bruton's Tyrosine Kinase)**: A versatile target in immune cell signaling, with implications across various diseases [4][10] Competitive Differentiation - **Mechanism of Action**: Bexabritadeg degrades BTK, removing both its enzymatic and scaffolding functions, unlike traditional kinase inhibitors which only block enzymatic activity [7][10] - **Potency**: Bexabritadeg is reported to be 10 to 100 times more potent than existing BTK inhibitors (Rizobrutinib and Remibrutinib) in blocking pathways related to immune cell activation [11] Clinical Development Plans - **Clinical Proof-of-Concept**: Expected to generate data on CLL patients with autoimmune hemolytic anemia by 2026, which may provide insights into broader autoimmune applications [12] - **New Formulation**: A new tablet formulation is being studied to enhance patient compliance and broaden the potential market for autoimmune diseases [13][14] Financial and Strategic Considerations - **Funding**: Nurix has $485 million in cash, sufficient to support operations through mid-2027 [38] - **Partnerships**: While partnerships could aid in financing, Nurix is currently well-funded to pursue development independently [15] Collaborative Pipeline - **IRAK4 and STAT6 Degraders**: Collaborations with Gilead and Sanofi for IRAK4 and STAT6 degraders, respectively, with significant market potential [19][22] - **Indication Selection**: Partners will drive indication selection for clinical proof-of-concept studies, with Nurix retaining options for profit-sharing in the U.S. [22][23] Upcoming Milestones - **Clinical Data Releases**: Key disclosures expected at upcoming conferences, including ESMO and ASH, with pivotal studies for Bexabritadeg planned for 2026 [38][39] Additional Insights - **Drug-Antibody Conjugates**: Potential applications in autoimmune diseases, emphasizing specificity and safety [35] - **Market Opportunities**: The autoimmune disease market is viewed as larger than oncology, with Bexabritadeg positioned to capture significant market share [12][14] Conclusion Nurix Therapeutics is strategically positioned with its innovative BTK degrader, Bexabritadeg, and a robust pipeline of collaborative projects. The company is focused on leveraging its unique mechanisms of action to differentiate itself in the competitive landscape of autoimmune and oncology treatments, with significant upcoming milestones that could enhance its market presence.

Group 1 - BMS is selling a 60% stake in its China joint venture, Shanghai BMS, to an affiliate of Hillhouse Capital, with the deal expected to close in early 2026 [1][4] - The divested assets include several products manufactured and sold exclusively in mainland China, such as Baraclude, Bufferin, and Theragran [1][4] - This divestiture is part of BMS's strategy to focus resources on core areas and optimize its business layout [1][4] Group 2 - Shanghai BMS was established in 1982 as the first Sino-American joint venture pharmaceutical company in China, predating other joint ventures like Xi'an Janssen and MSD [3] - The trend of foreign pharmaceutical companies exiting joint ventures in China is increasing, as the policy environment allows for wholly-owned operations [3][6] - Shanghai BMS has faced declining performance due to intensified competition and price reductions from centralized procurement, leading to a strategic decision to sell its business [4][6] Group 3 - In 2016, Shanghai BMS reported a record revenue of 4.72 billion yuan, but recent years have seen a decline in performance due to competition and pricing pressures [4] - The divestiture aligns with BMS's broader transformation plan, as the company reported a 2.48% year-over-year revenue decline in its latest financial report [4]

Investment Rating - The report indicates a positive outlook for the atopic dermatitis (AD) market, highlighting significant unmet medical needs and potential for new therapies, particularly in small molecules and biologics [4][10][12]. Core Insights - Atopic dermatitis is a chronic, recurrent inflammatory skin disease characterized by severe itching, affecting approximately 600-700 million patients globally, with around 67 million in China, indicating a substantial unmet demand for effective treatments [1][18][20]. - Recent advancements in small molecules and biologics have marked a new phase in AD treatment, with several new products entering the market, although the number remains limited [1][10][32]. - JAK inhibitors have shown excellent efficacy but come with safety concerns, while TYK2 inhibitors are emerging as a promising new option due to their selective action and potentially better safety profile [2][11][12]. - Biologics targeting IL-4Rα and IL-13 have demonstrated significant efficacy in improving skin lesions, with IL-31 showing strong itch relief capabilities [3][12][13]. - The development of dual/multi-target antibodies is seen as a new strategy to enhance treatment efficacy by combining the advantages of different targets [4][13][21]. Summary by Sections Investment Highlights - The AD market has immense potential, with a pressing need for effective therapies [4][10]. - The patient population is large, with over 600 million affected globally, necessitating urgent treatment options [1][18]. Disease Characteristics - AD is characterized by chronic inflammation and severe itching, significantly impacting patients' daily lives [1][14]. - The disease burden is heavy, with a complex pathogenesis involving multiple factors, primarily driven by Th2-type inflammation [21][24]. Current Treatment Landscape - Traditional therapies have safety concerns, leading to a shift towards biologics and small molecules [32][35]. - JAK inhibitors are the most approved class of drugs for AD, but they carry black box warnings due to safety issues [11][12]. - Emerging therapies, particularly TYK2 inhibitors, show promise for better safety and efficacy [2][11]. Biologics and Emerging Therapies - Currently approved biologics include IL-4Rα, IL-13, TSLP, and IL-31, with ongoing research into additional targets [3][12][13]. - Dual/multi-target antibodies are being explored to improve treatment outcomes and extend dosing intervals [4][13][21]. Market Potential - The report emphasizes the significant market potential for AD treatments, with projected growth driven by increasing patient numbers and the introduction of innovative therapies [4][10][20].

Group 1 - The 25th China International Investment and Trade Fair (CIFIT) showcased technological innovations and attracted over 123 countries and regions, with more than 8,000 business guests participating [1][2] - A total of 1,154 investment projects were signed at the event, with a planned total investment of 644 billion yuan, indicating a growing trend in China's bidirectional investment [2][3] - Foreign investment in China continues to increase, with Saudi Aramco establishing a joint venture in Fujian, reflecting confidence in China's market [3][4] Group 2 - ABB Group plans to increase its investment in China, particularly in Xiamen, emphasizing the importance of innovation and automation for sustainable development [4][5] - The establishment of the Non-Metallic Materials Innovation Center by Saudi Aramco and a Chinese research institute highlights the integration of foreign investment into China's technological innovation system [5][6] - Chinese companies are increasingly "going global," with examples like King Long Automobile showcasing new products and expanding into international markets [6][8] Group 3 - China's outbound direct investment reached 192.2 billion USD in 2024, maintaining a global share of 11.9%, indicating robust international investment activity [7][8] - The report indicates that over 30 countries participated in CIFIT to attract Chinese investments, showcasing the global interest in China's technological capabilities [8][9] - China has become a leader in R&D investment and patent applications, with significant advancements in emerging industries such as 5G and renewable energy [9][10] Group 4 - The CIFIT emphasized the importance of international innovation cooperation, with various technological innovations on display, including AI and new energy solutions [10][11] - ZF Group's commitment to increasing investment in China reflects the country's role as a vibrant innovation hub and a key market for new technologies [12]

Group 1: Investment Trends - The 25th China International Investment Trade Fair (CIFIT) attracted over 123 countries and regions, with more than 1,100 government and business delegations participating, showcasing China's growing investment landscape [1][2] - A total of 1,154 investment projects were signed at the event, with a planned total investment of 644 billion yuan, indicating a robust interest in investing in China [2] - China has maintained its position as a leading destination for foreign investment, with actual foreign investment reaching 116.24 billion USD in 2024, marking a 9.9% year-on-year increase in newly established foreign-invested enterprises [5][7] Group 2: Foreign Investment Insights - Saudi Aramco has established multiple joint ventures in China, with total investments exceeding 240 billion yuan, highlighting the company's confidence in the Chinese market [5] - ABB Group has committed to increasing its investment in China, particularly in Xiamen, emphasizing the importance of innovation and automation for sustainable development [6] - The high-tech industry accounted for 34.6% of foreign investment in China in 2024, with significant growth in medical equipment and technology services [7] Group 3: Chinese Enterprises Going Global - Chinese companies are increasingly expanding overseas, with 5.2 million enterprises established in 190 countries, and 1.9 million in Belt and Road Initiative countries [11] - The 2024 report indicated that China's outbound direct investment flow reached 192.2 billion USD, maintaining a global share of 11.9% [9][11] - Companies like King Long Bus are leveraging their innovations, such as autonomous delivery vehicles, to enhance their global market presence [9] Group 4: Technological Innovation and Collaboration - The CIFIT highlighted the importance of technological innovation, with many foreign companies shifting from bringing innovation to China to collaborating with Chinese firms on innovation [13][14] - Sanofi has integrated China into over 90% of its global development projects, showcasing China's role as a key player in global pharmaceutical innovation [13] - The establishment of innovation centers, such as the one by Saudi Aramco and the China Building Materials Academy, demonstrates the collaborative efforts in advancing technology [6][14]

Group 1: Event Overview - The 25th China International Investment and Trade Fair (CIFIT) was held in Xiamen, Fujian from September 8 to 11, showcasing a focus on technological innovation and attracting over 123 countries and regions, with more than 1100 government and business delegations and over 80,000 attendees [3][5]. - A total of 1154 investment projects were signed at the event, with a planned total investment of 644 billion yuan [5]. Group 2: Foreign Investment Insights - Foreign investment in China continues to grow, with Saudi Aramco establishing a joint venture in Fujian, reflecting confidence in the Chinese market [5][7]. - Saudi Aramco's investment in China exceeds 240 billion yuan, with plans for further collaboration in various sectors, particularly in green energy [7]. - The report indicates that in 2024, China attracted 116.24 billion USD in foreign investment, maintaining its position as a leading destination for foreign capital [10]. Group 3: Technological Innovation and Collaboration - The event highlighted the shift from "bringing innovation to China" to "innovating together with China," as foreign companies increasingly engage in collaborative innovation [17][19]. - Companies like Sanofi have integrated deeply into China's R&D ecosystem, participating in over 90% of global development projects [19]. - The focus on high-tech industries is evident, with foreign investment in high-tech sectors reaching 34.6% in 2024, particularly in medical devices and computer manufacturing [10]. Group 4: Chinese Companies Going Global - Chinese companies are increasingly expanding overseas, with a reported 192.2 billion USD in outbound direct investment in 2024, maintaining a global market presence [14]. - Companies like King Long Bus are innovating in autonomous delivery vehicles and expanding their market reach, including significant exports to countries like Chile [11][14]. - The trend of "going out" is supported by the establishment of over 52,000 enterprises in 190 countries, with a focus on infrastructure and green technology [15].

【环球时报特约记者 任重】英国制药业近段时间频遭打击。据英国广播公司（BBC）近日报道，英国 制药巨头阿斯利康9月12日发声明称决定停止其在剑桥研发基地投资2亿英镑的计划，而就在该声明发表 前不久，美国制药巨头默克公司也取消了原定10亿英镑的在英扩张计划，理由是英国政府对该行业投资 不足。 英国《卫报》援引分析人士的话报道称，在与多家大型药企首席执行官交流时发现"他们立场一致，均 表示不再对英国追加投资"。上周五，法国药企赛诺菲的英国市场准入主管保罗·奈什表示，英国需要出 台"针对生命科学产业的切实计划"，并指出该国已成为"不适合药品研发与销售之地"。 这是阿斯利康今年第二次撤回重大投资计划。今年1月，该公司放弃了在英格兰北部疫苗生产厂投资4.5 亿英镑的计划，当时公司将原因归咎于政府支持力度下降。此次的投资暂停意味着该公司去年3月宣布 的6.5亿英镑对英投资目前全部处于停滞状态。默克发言人称，默克公司取消投资反映出"英国在解决生 命科学产业投资不足，以及历届政府长期低估创新药物和疫苗价值方面未能取得实质性进展"。据悉， 默克已启动建设的伦敦国王十字基地原定2027年竣工，但现在宣布不再使用。 BBC报道称， ...

The U.K.-based AstraZeneca Plc AZN paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.AstraZeneca spokesperson told Reuters the company regularly reviews investment priorities and can confirm that the Cambridge expansion is on hold.The news deals a setback to Prime Minister Keir Starmer’s government just days before U.S. President Donald Trump’s state visit. Trump has slammed Britain and Europe for underpaying for drugs, while pharma companies warn that the UK’s ...